Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC, Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM, Kanaan NM, Paumier KL, El-Agnaf OMA, Sortwell CE.

Neurobiol Dis. 2019 Jul 2;130:104525. doi: 10.1016/j.nbd.2019.104525. [Epub ahead of print]

2.

Parkinson's Disease Biomarkers based on Alpha-synuclein.

Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA.

J Neurochem. 2019 Jul 2. doi: 10.1111/jnc.14809. [Epub ahead of print] Review.

PMID:
31265130
3.

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy.

Wu JZ, Ardah M, Haikal C, Svanbergsson A, Diepenbroek M, Vaikath NN, Li W, Wang ZY, Outeiro TF, El-Agnaf OM, Li JY.

Transl Neurodegener. 2019 Jun 15;8:18. doi: 10.1186/s40035-019-0159-7. eCollection 2019.

4.

Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.

Murakami H, Tokuda T, El-Agnaf OMA, Ohmichi T, Miki A, Ohashi H, Owan Y, Saito Y, Yano S, Tsukie T, Ikeuchi T, Ono K.

BMC Neurol. 2019 Jun 4;19(1):113. doi: 10.1186/s12883-019-1346-y.

5.

Antibodies against alpha-synuclein: tools and therapies.

Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA.

J Neurochem. 2019 May 4. doi: 10.1111/jnc.14713. [Epub ahead of print] Review.

PMID:
31055836
6.

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P.

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Review.

PMID:
30981640
7.

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid.

Kakuda K, Ikenaka K, Araki K, So M, Aguirre C, Kajiyama Y, Konaka K, Noi K, Baba K, Tsuda H, Nagano S, Ohmichi T, Nagai Y, Tokuda T, El-Agnaf OMA, Ogi H, Goto Y, Mochizuki H.

Sci Rep. 2019 Apr 12;9(1):6001. doi: 10.1038/s41598-019-42399-0.

8.

Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.

Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, Quiroga-Varela A, Chiasserini D, Mellone M, Mazzocchetti P, Calabrese V, Campanelli F, Mechelli A, Di Filippo M, Ghiglieri V, Picconi B, El-Agnaf OM, De Leonibus E, Gardoni F, Tozzi A, Calabresi P.

Brain. 2019 May 1;142(5):1365-1385. doi: 10.1093/brain/awz065.

9.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
10.

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.

van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.

Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15. Erratum in: Mov Disord. 2019 Jan;34(1):159.

11.

Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.

Vaikath NN, Erskine D, Morris CM, Majbour NK, Vekrellis K, Li JY, El-Agnaf OMA.

Neuropathol Appl Neurobiol. 2018 Nov 13. doi: 10.1111/nan.12531. [Epub ahead of print]

PMID:
30422353
12.

Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.

Donadio V, Incensi A, El-Agnaf O, Rizzo G, Vaikath N, Del Sorbo F, Scaglione C, Capellari S, Elia A, Stanzani Maserati M, Pantieri R, Liguori R.

Sci Rep. 2018 Sep 24;8(1):14246. doi: 10.1038/s41598-018-32588-8.

13.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.

J Neurochem. 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.

14.

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 29;15(1):169. doi: 10.1186/s12974-018-1202-9.

15.

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 1;15(1):129. doi: 10.1186/s12974-018-1171-z. Erratum in: J Neuroinflammation. 2018 May 29;15(1):169.

16.

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice.

Karampetsou M, Ardah MT, Semitekolou M, Polissidis A, Samiotaki M, Kalomoiri M, Majbour N, Xanthou G, El-Agnaf OMA, Vekrellis K.

Sci Rep. 2017 Nov 28;7(1):16533. doi: 10.1038/s41598-017-15813-8.

17.

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.

Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P; Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research.

Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Review.

18.

Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?

Sakaue S, Kasai T, Mizuta I, Suematsu M, Osone S, Azuma Y, Imamura T, Tokuda T, Kanno H, El-Agnaf OMA, Morimoto M, Nakagawa M, Hosoi H, Mizuno T.

NPJ Parkinsons Dis. 2017 Mar 31;3:13. doi: 10.1038/s41531-017-0014-4. eCollection 2017.

19.

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K.

Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. Review.

20.

Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.

Kruse N, El-Agnaf OM, Mollenhauer B.

Bioanalysis. 2017 Apr;9(8):621-630. doi: 10.4155/bio-2017-0005. Epub 2017 May 15.

PMID:
28504552
21.

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.

Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED, Nussbaum RL, Majbour NK, El-Agnaf OM, Bennett SA, Lagace DC, Woulfe JM, Sad S, Brown EG, Schlossmacher MG.

J Neural Transm (Vienna). 2017 Jun;124(6):721-738. doi: 10.1007/s00702-017-1726-7. Epub 2017 May 5.

22.

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

El-Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2017 Aug;104:85-96. doi: 10.1016/j.nbd.2017.05.002. Epub 2017 May 2.

23.

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease.

Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, Parnetti L, Calabresi P, El-Agnaf OM.

Sci Rep. 2017 Jan 10;7:40263. doi: 10.1038/srep40263.

24.

Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum.

Sharrad DF, Chen BN, Gai WP, Vaikath N, El-Agnaf OM, Brookes SJ.

Neurogastroenterol Motil. 2017 Apr;29(4). doi: 10.1111/nmo.12985. Epub 2016 Nov 7.

PMID:
27997067
25.

Cognitive impairment in Parkinson's disease.

Majbour N, El-Agnaf O.

Lancet Neurol. 2017 Jan;16(1):23-24. doi: 10.1016/S1474-4422(16)30329-5. Epub 2016 Nov 18. No abstract available.

PMID:
27866857
26.

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.

Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D.

Mol Neurodegener. 2016 Aug 22;11(1):61. doi: 10.1186/s13024-016-0125-0.

27.

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.

Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, Haque ME, Tokuda T, Auinger P, Calabresi P, Parnetti L, El-Agnaf OM.

Mov Disord. 2016 Oct;31(10):1535-1542. doi: 10.1002/mds.26754.

PMID:
27548849
28.

Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function.

Kim DK, Lim HS, Kawasaki I, Shim YH, Vaikath NN, El-Agnaf OM, Lee HJ, Lee SJ.

Autophagy. 2016 Oct 2;12(10):1849-1863. Epub 2016 Aug 2.

29.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

30.

Glycation in Parkinson's disease and Alzheimer's disease.

Vicente Miranda H, El-Agnaf OM, Outeiro TF.

Mov Disord. 2016 Jun;31(6):782-90. doi: 10.1002/mds.26566. Epub 2016 Mar 4. Review.

PMID:
26946341
31.

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.

Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf OM.

Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9.

32.

Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice.

Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OM, Ulusoy A, Di Monte DA.

Brain. 2016 Mar;139(Pt 3):856-70. doi: 10.1093/brain/awv376. Epub 2015 Dec 30.

PMID:
26719384
33.

Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.

Javed H, Menon SA, Al-Mansoori KM, Al-Wandi A, Majbour NK, Ardah MT, Varghese S, Vaikath NN, Haque ME, Azzouz M, El-Agnaf OM.

Mol Ther. 2016 Apr;24(4):746-58. doi: 10.1038/mt.2015.232. Epub 2015 Dec 24. Erratum in: Mol Ther. 2016 Apr;24(4):843.

34.

Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.

Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampà C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Björklund A, Spillantini MG, Picconi B, Calabresi P.

Biol Psychiatry. 2016 Mar 1;79(5):402-414. doi: 10.1016/j.biopsych.2015.08.013. Epub 2015 Aug 20.

PMID:
26392130
35.

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.

Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M, Mollenhauer B.

Biomark Med. 2016;10(1):19-34. doi: 10.2217/BMM.14.105. Epub 2015 Aug 28. Review.

PMID:
26314196
36.

Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.

Lawand NB, Saadé NE, El-Agnaf OM, Safieh-Garabedian B.

Expert Opin Ther Targets. 2015;19(10):1351-60. doi: 10.1517/14728222.2015.1062877. Epub 2015 Jul 1. Review.

PMID:
26135549
37.

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM.

Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30.

PMID:
25937088
38.

Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.

Ishii R, Tokuda T, Tatebe H, Ohmichi T, Kasai T, Nakagawa M, Mizuno T, El-Agnaf OM.

PLoS One. 2015 Apr 7;10(4):e0123162. doi: 10.1371/journal.pone.0123162. eCollection 2015.

39.

Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.

Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.

Neurobiol Dis. 2015 Jun;78:100-14. doi: 10.1016/j.nbd.2015.03.008. Epub 2015 Mar 25.

PMID:
25818009
40.

Detection of oligomers and fibrils of α-synuclein by AIEgen with strong fluorescence.

Leung CW, Guo F, Hong Y, Zhao E, Kwok RT, Leung NL, Chen S, Vaikath NN, El-Agnaf OM, Tang Y, Gai WP, Tang BZ.

Chem Commun (Camb). 2015 Feb 4;51(10):1866-9. doi: 10.1039/c4cc07911f.

PMID:
25526628
41.

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, Safieh-Garabedian B, Al-Hayani AA, Eliezer D, Li M, El-Agnaf OM.

Neurobiol Dis. 2015 Feb;74:89-101. doi: 10.1016/j.nbd.2014.11.007. Epub 2014 Nov 15.

42.

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Aasly JO, Johansen KK, Brønstad G, Warø BJ, Majbour NK, Varghese S, Alzahmi F, Paleologou KE, Amer DA, Al-Hayani A, El-Agnaf OM.

Front Aging Neurosci. 2014 Sep 25;6:248. doi: 10.3389/fnagi.2014.00248. eCollection 2014.

43.

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity.

Ardah MT, Paleologou KE, Lv G, Abul Khair SB, Kazim AS, Minhas ST, Al-Tel TH, Al-Hayani AA, Haque ME, Eliezer D, El-Agnaf OM.

Front Aging Neurosci. 2014 Aug 5;6:197. doi: 10.3389/fnagi.2014.00197. eCollection 2014.

44.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM.

Alzheimers Res Ther. 2014 May 7;6(3):25. doi: 10.1186/alzrt255. eCollection 2014.

45.

Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid.

Persichetti E, Chiasserini D, Parnetti L, Eusebi P, Paciotti S, De Carlo C, Codini M, Tambasco N, Rossi A, El-Agnaf OM, Calabresi P, Beccari T.

PLoS One. 2014 Jul 1;9(7):e101453. doi: 10.1371/journal.pone.0101453. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114809. El Agnaf, Omar M [corrected to El-Agnaf, Omar M A].

46.

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.

Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour NK, El-Agnaf O, Calabresi P.

Front Aging Neurosci. 2014 Mar 31;6:53. doi: 10.3389/fnagi.2014.00053. eCollection 2014.

47.

Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Kasai T, Tokuda T, Ishii R, Ishigami N, Tsuboi Y, Nakagawa M, Mizuno T, El-Agnaf OM.

J Neurol. 2014 Jun;261(6):1203-9. doi: 10.1007/s00415-014-7334-7. Epub 2014 Apr 16.

PMID:
24737170
48.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P.

Mov Disord. 2014 Jul;29(8):1019-27. doi: 10.1002/mds.25772. Epub 2014 Jan 16.

49.

The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.

Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OM, Kostic V, Markovic I, Trajkovic V.

Neurobiol Dis. 2014 Mar;63:1-11. doi: 10.1016/j.nbd.2013.11.002. Epub 2013 Nov 20.

PMID:
24269733
50.

The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.

Al-Mansoori KM, Hasan MY, Al-Hayani A, El-Agnaf OM.

Curr Alzheimer Res. 2013 Jul;10(6):559-68. Review.

PMID:
23899170

Supplemental Content

Loading ...
Support Center